LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p

[1]  S. Ju,et al.  Serum level of long noncoding RNA H19 as a diagnostic biomarker of multiple myeloma. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[2]  F. Ji,et al.  Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21. , 2018, Oncology letters.

[3]  P. Kapoor,et al.  Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies , 2018, Current Hematologic Malignancy Reports.

[4]  F. Efficace,et al.  Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review , 2018, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

[5]  P. Howe,et al.  The Long (lncRNA) and Short (miRNA) of It: TGFβ-Mediated Control of RNA-Binding Proteins and Noncoding RNAs , 2018, Molecular Cancer Research.

[6]  Dae Hyun Lee,et al.  Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention , 2018, Current Treatment Options in Cardiovascular Medicine.

[7]  L. Plank,et al.  Differential mRNA expression of the main apoptotic proteins in normal and malignant cells and its relation to in vitro resistance , 2018, Cancer Cell International.

[8]  Chendong Yang,et al.  Kanglaite reverses multidrug resistance of HCC by inducing apoptosis and cell cycle arrest via PI3K/AKT pathway , 2018, OncoTargets and therapy.

[9]  H. Fang,et al.  Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents. , 2018, European journal of medicinal chemistry.

[10]  Ning Hu,et al.  RETRACTED ARTICLE: Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression , 2018, Cell cycle.

[11]  W. Kerwin,et al.  Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition , 2017, Scientific Reports.

[12]  P. Dehghan,et al.  Enhancement of chemosensitivity by simultaneously silencing of Mcl-1 and Survivin genes using small interfering RNA in human myelomonocytic leukaemia , 2017, Artificial cells, nanomedicine, and biotechnology.

[13]  K. Kimura,et al.  Long non‐coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma , 2017, British journal of haematology.

[14]  Junxia Chen,et al.  lncRNA H19 regulates epithelial-mesenchymal transition and metastasis of bladder cancer by miR-29b-3p as competing endogenous RNA. , 2017, Biochimica et biophysica acta. Molecular cell research.

[15]  D. Hao,et al.  Long Noncoding RNA CRNDE Promotes Multiple Myeloma Cell Growth by Suppressing miR-451. , 2017, Oncology research.

[16]  Huan Yao,et al.  LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma , 2017, Cell Death & Disease.

[17]  Lei Chen,et al.  Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis , 2017, Bioscience reports.

[18]  S. Lonial,et al.  Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. , 2017, Blood.

[19]  S. Ševčíková,et al.  Deregulated expression of long non‐coding RNA UCA1 in multiple myeloma , 2017, European journal of haematology.

[20]  S. Kang,et al.  Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma , 2016, Leukemia & lymphoma.

[21]  R. Orlowski,et al.  The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma* , 2015, The Journal of Biological Chemistry.

[22]  J. Keats,et al.  Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma. , 2015, Cancer cell.

[23]  Xiaoqin Zhang,et al.  Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma , 2015, Molecular Cancer.

[24]  Wei Zhang,et al.  H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation , 2015, Tumor Biology.

[25]  Ping Chen,et al.  Upregulation of lncRNA MEG3 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells From Multiple Myeloma Patients By Targeting BMP4 Transcription , 2015, Stem cells.

[26]  Yan Peng,et al.  H19 lncRNA mediates 17β-estradiol-induced cell proliferation in MCF-7 breast cancer cells. , 2015, Oncology reports.

[27]  G. Kroemer,et al.  MCL-1 dependency of cisplatin-resistant cancer cells. , 2014, Biochemical pharmacology.

[28]  Tsuyoshi Saito,et al.  BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer. , 2014, Gynecologic oncology.

[29]  J. Keats,et al.  Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. , 2013, Cancer cell.

[30]  L. Staudt,et al.  Control of autophagic cell death by caspase-10 in multiple myeloma. , 2013, Cancer cell.

[31]  G. Mulligan,et al.  Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. , 2012, Blood.

[32]  J. Naval,et al.  Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy. , 2012, Leukemia research.

[33]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[34]  R. Hegele.  Making sense of cell surface nucleolin: Implications for respiratory syncytial virus prophylaxis and therapy , 2012, Cell cycle.

[35]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[36]  S Iida,et al.  Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress , 2010, Leukemia.

[37]  KyungMann Kim,et al.  Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells , 2008, Molecular Cancer Research.

[38]  F. Schmidt.  Meta-Analysis , 2008 .

[39]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[40]  E. Terpos,et al.  No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. , 2006, Leukemia research.

[41]  D. Demetrick,et al.  The human thrombin receptor gene and the 5q-syndrome. , 1997, Leukemia & lymphoma.

[42]  S. Ju,et al.  Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. , 2017, Cancer biomarkers : section A of Disease markers.

[43]  S. Fesik,et al.  Small molecule Mcl-1 inhibitors for the treatment of cancer. , 2015, Pharmacology & therapeutics.

[44]  Q. Wang,et al.  Aflatoxin B1 promotes cell growth and invasion in hepatocellular carcinoma HepG2 cells through H19 and E2F1. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[45]  P. Richardson,et al.  A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. , 2014, Blood.

[46]  M. Peck-Radosavljevic,et al.  Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. , 2006, Journal of hepatology.